| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Cardamonin targets multiple pathways. It is a novel antagonist of the human TRPA1 cation channel with an IC50 of 454 nM. It also inhibits the NF-κB pathway by suppressing p65NF-κB nuclear translocation and I-κBα phosphorylation. Additionally, it inhibits NO and PGE2 production.
|
|---|---|
| ln Vitro |
(E)-Cardamomomin does not interact with TRPV1 or TRPV4 channels, but instead preferentially inhibits TRPA1 activation (IC50=454 nM). Cardamomin's docking research indicated a compatible interaction with TRPA1's A-967079 binding site. (E)-Cardamomomin ((E)-Cardamomomin) did not significantly affect cardiomyocyte contraction or HEK293 cell viability [1]. Tgase-2, cyclooxygenase-2 (COX-2), and p65 (nuclear factor-κB) expression are all inhibited by (E)-Cardamomomin in a concentration-dependent manner, but IκB expression is restored in MG63 and Raw264.7 cells [2].
In vitro, Cardamonin (20, 40, and 80 mg/kg, intragastric) reduces inflammation in rats, demonstrating its systemic anti-inflammatory effects. It inhibits NO and PGE2 production from LPS- and IFN-γ-induced RAW cells and inhibits TXB2 production via the COX-1 and COX-2 pathways. |
| ln Vivo |
(E)-Cardamomomin ((E)-Cardamomomin) (3-30 mg/kg, orally) dramatically reduces the writhing caused by PBQ. Additionally, carrageenan-induced hyperalgesia's withdrawal latency increases significantly in response to CDN in a dose-dependent manner [2].
In vivo, Cardamonin shows anti-inflammatory activity in various models. It inhibits NF-κB activation via inhibition of IκBα degradation and phosphorylation, IκB kinase activation, and NF-κB nuclear translocation. These effects contribute to its anticancer and anti-inflammatory properties. |
| Enzyme Assay |
The in vitro receptor binding assay for Cardamonin involves measuring its antagonist activity at the hTRPA1 cation channel. This is typically performed using calcium flux assays in cells overexpressing the TRPA1 channel, where the compound's ability to block agonist-induced calcium influx is measured.
|
| Cell Assay |
In vitro cell-based assays are performed in RAW 264.7 macrophage cells. Cells are stimulated with LPS and IFN-γ to induce an inflammatory response. The production of NO and PGE2 is then measured in the presence and absence of Cardamonin to assess its anti-inflammatory activity.
|
| Animal Protocol |
In vivo activity is evaluated in animal models of inflammation, such as the rat model. Cardamonin is administered via intragastric gavage, and serum levels of pro-inflammatory molecules are measured to assess its systemic anti-inflammatory effect.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Cardamonin are not extensively detailed. As a natural product with oral activity (intragastric administration), it is likely absorbed and systemically distributed. Further studies would be needed to fully characterize its ADME profile.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for Cardamonin is not available in the standard research literature. As a naturally occurring compound with a history of use in traditional medicine, it is generally considered to have a low toxicity profile, but systematic studies are lacking.
|
| References |
|
| Additional Infomation |
Cardamonin belongs to the chalcone class of compounds. Cardamonin (also known as dihydroxymethoxychalcone) has attracted considerable attention from the scientific community due to its health benefits, and the number of related publications is constantly increasing. The name Cardamonin comes from its presence in cardamom spices. Cardamonin has been reported to be found in Toona sinensis (Cedrelopsis grevei), turmeric (Boesenbergia rotunda), and other organisms with relevant data.
Cardamonin is a promising natural product lead for drug development, particularly for inflammatory diseases and cancer. Its multi-targeted mechanism of action, including TRPA1 antagonism and NF-κB inhibition, makes it a valuable tool for studying these pathways. It is not an approved drug. |
| Molecular Formula |
C16H14O4
|
|---|---|
| Molecular Weight |
270.2800
|
| Exact Mass |
270.089
|
| CAS # |
19309-14-9
|
| Related CAS # |
Cardamonin; 18956-16-6; (E)-Cardamonin; 19309-14-9
|
| PubChem CID |
641785
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
484.5±45.0 °C at 760 mmHg
|
| Flash Point |
182.7±22.2 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.658
|
| Source |
Originated from plants: Zingiberaceae Alpinia katsumadai Hayata
|
| LogP |
3.62
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
346
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC(=CC(=C1C(=O)/C=C/C2=CC=CC=C2)O)O
|
| InChi Key |
NYSZJNUIVUBQMM-BQYQJAHWSA-N
|
| InChi Code |
InChI=1S/C16H14O4/c1-20-15-10-12(17)9-14(19)16(15)13(18)8-7-11-5-3-2-4-6-11/h2-10,17,19H,1H3/b8-7+
|
| Chemical Name |
(E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 28 mg/mL (~103.60 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 15 mg/mL (55.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (150.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6999 mL | 18.4993 mL | 36.9987 mL | |
| 5 mM | 0.7400 mL | 3.6999 mL | 7.3997 mL | |
| 10 mM | 0.3700 mL | 1.8499 mL | 3.6999 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
